Summer Street talks Amarin, Vascepa amid sell-off

|About: Amarin Corporation PLC (AMRN)|By:, SA News Editor

As the stock sells-off on this morning's FDA news, Summer Street is out with some commentary on Amarin (AMRN -10.3%).

"We believe that AMRN has almost no chance of getting the FDA to approve Vascepa for treating moderate triglycerides without outcomes data," Bart Classen says.

"A positive outcome trial is a long shot because no agent has ever shown an outcome benefit over statins." the analyst adds for good measure.